{"Clinical Trial ID": "NCT00022672", "Intervention": ["INTERVENTION 1:", "Trastuzumab + Anastrozole", "Trastuzumab 4 mg/kg intravenous load dose (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole per day for 24 months in the main and extension phases.", "INTERVENTION 2:", "Anastrozole", "During the main phase, 1 mg of oral anastrozole daily for 24 months. During the extension phase, participants could also receive trastuzumab 4 mg/kg of initial intravenous loading (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes."], "Eligibility": ["Incorporation criteria:", "Menopausal women;", "Metastatic breast cancer is suitable for endocrine treatment;", "Positive status of hormonal receptors;", "Overexpression of human epidermal growth factor receptor 2 (HER2).", "- Exclusion criteria:", "Patients on hormone replacement therapy;", "Previous chemotherapy for metastatic diseases;", "\u2022 Uncontrolled heart disease and a history of heart failure."], "Results": ["Performance measures:", "- Progression-free survival (PFS)", "For two-dimensional malignant lesions with an area of at least 2.0 square centimetres (cm^2), an increase of 1.0 cm^2 was required and for one-dimensional lesions of 1.0 cm or less, an increase of 0.5 cm was required. PFS was defined as the number of days between the date of randomization and the date of documented progression of the disease or the date of death.", "Duration: 24 months, end of study (up to 5 years)", "Results 1:", "Title of the arm/group: Trastuzumab + Anastrozole", "Description of the arm/group: Trastuzumab 4 mg/kg intravenous load dose (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole per day for 24 months in the main and extension phases.", "Total number of participants analysed: 103", "Median (95% confidence interval)", "Unit of measure: month 24 months: 4.8 (3.7 to 7)", "End of study: 5.8 (4.6 to 8.3)", "Results 2:", "Title of the arm/group: Anastrozole", "In the prolongation phase, participants could also receive trastuzumab 4 mg/kg intravenous initial load (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes.", "Total number of participants analysed: 104", "Median (95% confidence interval)", "Unit of measure: month 24 months: 2.4 (2 to 4.6)", "End of study: 2.9 (2.1 to 4.5)"], "Adverse Events": ["Undesirable Events 1:", "Total: 25/103 (24.27 per cent)", "Febrile neutropenia 1/103 (0.97%)", "Myocardial infarction 1/103 (0.97%)", "Myocardial Ischemia 1/103 (0.97%)", "Inflammation of the middle ear 1/103 (0.97%)", "- Vomiting 3/103 (2.91 per cent)", "Nausea 2/103 (1.94%)", "Abdominal pain 1/103 (0.97%)", "Constipation 1/103 (0.97%)", "Diarrhoea 1/103 (0.97%)", "Gastritis 1/103 (0.97%)", "Intestinal occlusion 1/103 (0.97%)", "Adverse Events 2:", "Total: 6/104 (5.77%)", "Febrile neutropenia 1/104 (0.96%)", "Myocardial infarction 1/104 (0.96%)", "Myocardial ischemia 0/104 (0.00 %)", "Inflammation of the middle ear 0/104 (0.00 %)", "Vomiting 0/104 (0.00 %)", "Nausea 0/104 (0.00 %)", "Abdominal pain 0/104 (0.00 %)", "Constipation 0/104 (0.00 %)", "Diarrhoea 0/104 (0.00 %)", "Gastritis 0/104 (0.00 %)", "Intestinal occlusion 0/104 (0.00 %)"]}